Cargando…

Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review

OBJECTIVE: Behçet’s Disease (BD) is an intractable systemic vasculitis. When accompanied by intestinal symptoms, the prognosis is usually poor. 5-Aminosalicylic acid (5-ASA), corticosteroids, immunosuppressive drugs, and anti-tumor necrosis factor-α (anti-TNF-α) biologics are standard therapies to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ruixia, Li, Xiaofei, Zhou, He, Shi, Yanting, Wang, Fang, Wu, Tong, Liang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242066/ https://www.ncbi.nlm.nih.gov/pubmed/37287984 http://dx.doi.org/10.3389/fimmu.2023.1205046

Ejemplares similares

Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease
por: Arbrile, Marta, et al.
Publicado: (2021)

Case report: Refractory intestinal Behçet’s syndrome successfully treated with tofacitinib: A report of four cases
por: Zhao, Na, et al.
Publicado: (2022)

Apremilast in Refractory Behçet’s Syndrome: A Multicenter Observational Study
por: Vieira, Matheus, et al.
Publicado: (2021)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Immunopathogenesis of Behcet's Disease
por: Tong, Bainan, et al.
Publicado: (2019)

Tofacitinib as an alternative therapy for refractory intestinal Behçet’s syndrome
por: Zou, Jun, et al.
Publicado: (2022)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease
por: Kaji, Mariko, et al.
Publicado: (2015)

Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018)

Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis
por: Zhan, Shukai, et al.
Publicado: (2022)

Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab
por: Trentadue, Guido, et al.
Publicado: (2020)

A20 Haploinsufficiency in a Chinese Patient With Intestinal Behcet's Disease-Like Symptoms: A Case Report
por: Chen, Yu, et al.
Publicado: (2020)

Chemokines and chemokine receptors in Behçet’s disease
por: Li, Zhan, et al.
Publicado: (2023)

Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease
por: Nakamura, Akihiro, et al.
Publicado: (2016)

Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis
por: Li, Allen Cheng-Wei, et al.
Publicado: (2022)

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study
por: Qi, Xiaofei, et al.
Publicado: (2018)

Case report and analysis: Behçet’s disease with lower extremity vein thrombosis and pseudoaneurysm
por: Wang, Han-Lu, et al.
Publicado: (2022)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Behçet’s Disease: An Overview of Etiopathogenesis
por: Leccese, Pietro, et al.
Publicado: (2019)

Neutrophil Extracellular Traps Promote Aberrant Macrophages Activation in Behçet’s Disease
por: Li, Lu, et al.
Publicado: (2021)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022)

Behçet's Disease Under Microbiotic Surveillance? A Combined Analysis of Two Cohorts of Behçet's Disease Patients
por: van der Houwen, Tim B., et al.
Publicado: (2020)

Behçet's disease with intestinal involvement: a case report and review of the literature
por: Li, Lin, et al.
Publicado: (2023)

Treating the Different Phenotypes of Behçet's Syndrome
por: Bettiol, Alessandra, et al.
Publicado: (2019)

The role of miRNAs in Behçet’s disease
por: Gu, Feihan, et al.
Publicado: (2023)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Candidate Drugs Screening for Behcet’s Disease Based on Bioinformatics Analysis and Mouse Experiments
por: Xia, Qinyun, et al.
Publicado: (2022)

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
por: Park, Jihye, et al.
Publicado: (2017)

Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet’s Disease and Refractoriness to Treatment
por: Furuta, Yoki, et al.
Publicado: (2023)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
por: Diana, Pietro, et al.
Publicado: (2018)

α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
por: Filip, Rafał, et al.
Publicado: (2019)

Case report: Induction and maintenance of steroid-free remission with vedolizumab in a case of steroid-dependent autoimmune pancreatitis
por: Griebel, Paul, et al.
Publicado: (2023)

Cytokine Signatures in Mucocutaneous and Ocular Behçet’s Disease
por: Lopalco, Giuseppe, et al.
Publicado: (2017)

The complex HLA-E-nonapeptide in Behçet disease
por: Castaño-Núñez, Ángel Luís, et al.
Publicado: (2023)

Case report: Successful treatment of refractory membranous nephropathy with telitacicept
por: Zhang, Lei, et al.
Publicado: (2023)

Behçet's disease-induced massive small intestinal bleeding successfully treated with adalimumab
por: Liu, PH, et al.
Publicado: (2023)

Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience
por: Park, Jihye, et al.
Publicado: (2018)

Understanding Behçet’s Disease in the Context of Innate Immunity Activation
por: Perazzio, Sandro F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qfsaal7up276c0ltukpgt7df4s